BICOLL ANNOUNCES DR. MICHAEL BOGENSTAETTER AS NEW ADVISORY BOARD MEMBER

DR. MICHAEL BOGENSTAETTER OFFICIALLY APPOINTED TO JOIN BICOLL’S ADVISORY BOARD

Munich, Germany – June 3rd, 2009 – The Bicoll GmbH, a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields, today announces the appointment of Dr. Michael Bogenstaetter as new member of the Advisory Board. After a one year period of getting acquainted with Bicoll’s business model and business segments, Dr. Bogenstaetter will now officially join the long-term advisors Dr. Hardy Debuch, Prof. Dr. Thorsten Bach, Prof. Dr. Peter Vollhardt and Sina Afra.

Dr. Bogenstaetter has over 15 years experience in biopharmaceutical research and life science management & strategy. He is one of the few experts who have a deep knowledge spanning from pharmaceutical research (academia, J&J) to commercial & strategic objectives (Novartis, The Boston Consulting Group). Currently, he is VP of Strategy & Corporate Development at MDS Inc., driving strategic acquisitions and divestitures.

'Michael’s extensive knowledge in biopharmaceutical research and strategic issues will provide a significant impact on Bicoll's growth strategy,' commented Dr. Kai Lamottke, Founder & Managing Director of Bicoll GmbH. 'Over the last 12 months Bicoll could already benefit from his broad experience and deep strategic insights into the pharmaceutical market.”

“Working closely with Bicoll’s leadership team and Advisory Board for over 12 months allowed me to develop inside and appreciation of the company’s unique capabilities and tremendous accomplishments to date,” attested also Dr. Bogenstaetter. “Leveraging biodiversity to discover novel medicines has solid precedent and proven commercial success; Bicoll uniquely positioned itself to bring this paradigm to a renaissance through its quantum leap approach and technology advancement. It is a real privilege to continue contributing to this endeavor.”

About Bicoll
Bicoll is a biopharmaceutical company specializing in high-tech natural product chemistry to identify novel small molecules for drug discovery and related innovative fields. The research focus is on making compounds from natural resources compatible with customers' screening systems for drug discovery and various other fields of application. Bicoll's advanced approach of property-based screening selects promising candidates early on and avoids investment in less promising compounds. Bicoll's products and additional services, like custom synthesis, are tailored to its customers' needs to accelerate the development process of new pharmaceuticals.

The Bicoll Group provides its services to a number of international clients of various fields of interest, e.g. pharmaceutical and agrochemical industry. The Bicoll Group was founded in 2000 and comprises two legal entities: Bicoll GmbH in Munich, Germany and Bicoll Biotechnology (Shanghai) Co. Ltd., P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai. Bicoll currently employs 35 people at both locations.


Dr. Nicole Feling
Public Relations Management

Bicoll GmbH
Richard-Riemerschmid-Allee 27
81241 München
Germany

Tel.: 0049-(0)89-82072564
E-Mail: nicole.feling@bicoll-group.com

www.bicoll-group.com

Bicoll